It is a common perception that approximately 50% of heart failure (HF) patients present with a normal or near-normal left ventricular (LV) ejection fraction ("HF with preserved systolic function"), ...
The multicenter trial coordinated by the Research Centre of Applied and Preventive Cardiovascular Medicine at the University of Turku shows that low socioeconomic status in childhood increases the ...
Cardiomyopathy is the leading cause of mortality in patients with DMD. Compared with their healthy counterparts, patients with DMD — including those with preserved left ventricular ejection fraction ...
Echocardiographic data analysis demonstrated favorable impact of atrioventricular interval modulation (“AVIM”) therapy on MODERATO II study patients with diastolic dysfunction, a key component in the ...
The study covered in this summary was published on ResearchSquare.com as a preprint and has not yet been peer-reviewed. The addition of the SGLT2 inhibitor empagliflozin to routine acute coronary ...
There may be a future for cardiac myosin inhibitors in heart failure with preserved ejection fraction (HFpEF), according to the proof-of-concept EMBARK-HFpEF trial. An established cardiac myosin ...
Heart failure occurs when the heart can't pump blood as well as it should. It can affect either the left side of the heart (left-sided heart failure) or the right side (right-sided heart failure).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback